Price Alert

DURECT Corporation (DRRX)

NASDAQ: DRRX · Real-Time Price · USD

1.92

0.01 (0.52%)

At close: Aug 18, 2025, 1:13 PM

0.52% (1D)

Bid	1.91
Market Cap	59.45M
Revenue (ttm)	525K
Net Income (ttm)	-4.91M
EPS (ttm)	-0.43
PE Ratio (ttm)	-4.45
Forward PE	-2.67
Analyst	Hold

Ask	2.43
Volume	500,384
Avg. Volume (20D)	1,015,701
Open	1.90
Previous Close	1.91
Day's Range	1.89 - 1.92
52-Week Range	0.48 - 2.64
Beta	0.84

About DRRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DRRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DRRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

DURECT has released their quartely earnings on Aug 12, 2025:

Revenue of $447K exceeds estimates by $127K, with -30.80% YoY decline.

EPS of -0.07 exceeds estimates by 0.06, with 41.67% YoY growth.

Next Earnings Release

DURECT Corporation is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+240.15%

DURECT shares are trading higher after announcing ... Unlock content with Pro Subscription

News

6 days ago · zacks.com

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago.

2 weeks ago · benzinga.com

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.

2 weeks ago · businesswire.com

DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is ...

2 weeks ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health. Click here to...

2 weeks ago · accessnewswire.com

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...